Synta Pharmaceuticals Corp. SNTA today announced the completion of the sale of 1,050,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters of its previously announced public offering.
After underwriting discounts and commissions and estimated offering expenses payable by Synta, aggregate net proceeds from the offering were approximately $32.9 million.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in